

1 **Title**

2 Prevention of cyclical resurgences of COVID-19-like pandemics in the long term:  
3 What are the trade-offs?  
4

5  
6 **Authors**

7 Ichiro Nakamoto<sup>1\*</sup>  
8  
9

10 **Affiliations**

11 <sup>1</sup> School of Internet Economics and Business,  
12 Fujian University of Technology, Fuzhou, Fujian Province, China.

13 \*Corresponding author Email: [ichiro2019@163.com](mailto:ichiro2019@163.com).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47

## 48 **Abstract**

49 Vaccines have facilitated the substantial reduction and containment of COVID-19 transmission in  
50 many countries by early 2023. However, the long-term interconnection between vaccines, traits  
51 of the pathogen, vaccination strategies, and cases averted/trade-offs of health outcomes is not  
52 well understood. Utilizing a compartment-calibrated model, I estimated the aversion/trade-offs  
53 effect on six major disease burdens (i.e., total/symptomatic/asymptomatic/hospitalized/ICU/death  
54 cases averted) over time conditional on a variety level of scenarios. The findings implied that  
55 low-risk immunity profiles of booster doses increased the peak cases averted versus medium- and  
56 high-risk counterparts. The effect was most salient for the former paired with enhancing the  
57 rollout rate of doses, followed by the medium- and then high-risk scenarios. Positive and  
58 temporarily durable aversion effects for the low-risk, in contrast, negative trade-offs and  
59 decreasing aversion effects for the suboptimal scenarios were observed. While there are  
60 heterogeneities in vaccines, public strategies, social efforts, and other considerations, this work  
61 can provide an evidence-based rationale for the long-term trade-off analysis of vaccination.  
62

63

64

## 64 **Introduction**

65 As of April 2023, a total of over 13 billion doses of COVID-19 vaccines have been administered  
66 globally (1-4), which has facilitated the mitigation and containment of SARS-COV-2  
67 transmission by this time. Different countries enacted varied campaigns of vaccination in  
68 compliance with the objectives of health policies to balance the trade-offs between the health  
69 output of the populations and economic activities (2,3). Retrospectively, vaccines, transmission  
70 traits of the pathogen, and vaccination strategies had a combined impact on the risks of infections  
71 and subsequent health outcomes (5-10). The data by WHO indicated that there were more than  
72 100 vaccine candidates in clinical usage worldwide by 2023 (1-4). It was of difficulty to exactly  
73 capture each of the traits of alternative vaccines in model analyses (11-15). There were  
74 heterogeneities and uncertainties regarding the landscape of vaccination, immunity-strength and  
75 immunity-waning profiles of doses, and the social effort (1-5, 16-20). Is there a long-term  
76 difference in curbing infections and other disease burdens by enacting the booster vaccination  
77 versus a primary strategy conditional on the traits of vaccines? How the effect is impacted by the  
78 vaccination strategy such as the rollout rate of doses? Furthermore, how to evaluate the potential  
79 trade-offs should the immunity profiles of vaccines present heterogeneities? What lessons can be  
80 learned from the COVID-19 pandemic to assess the next risk of cyclical resurgence of a novel  
81 infectious disease? Should early booster doses for a novel pandemic unveil suboptimal or multi-  
82 staged efficacy, where is the potential threshold of trade-offs? Here, I utilized a compartment-  
83 calibrated model to mostly capture the risks of infections and reinfections, vaccine inefficacy,  
84 immunity strength/waning of vaccines, rate of rollout, and other confounding factors to project  
85 the cases averted and trade-offs in the risk appraisal of cyclical resurgences of a COVID-19-like  
86 pandemic for six stratified health metrics (i.e.,  
87 total/symptomatic/asymptomatic/hospitalized/ICU/death cases averted) over a timescale of up to  
88 5 years.

89

## 90 **Methods**

91 Concisely, the transmission of COVID-19-like infectious diseases was divided into multiple  
92 compartments, of which primary infections (i.e., initial infections in full susceptibility),  
93 reinfections due to waning immunity after recovery (i.e., secondary infections), infections due to  
94 inefficacy or multi-staged traits of vaccines after booster vaccination (the rate of which was  
95 defined as VI hereafter), immunity waning to susceptibility after booster vaccination (likewise,

96 the rate of which was defined as VS), infections due to immunity waning after booster  
97 vaccination (the rate of which was defined as SI), recovery from infections, immunity waning to  
98 susceptibility after recovery, rates of vaccination, and vaccination were the major appraised  
99 factors in this study (fig. S1, 20-28). The metrics VI, SI, and VS reflected the immunity-strength  
100 and immunity-waning profile of booster doses. Theoretically, the greater values of the measures,  
101 the lower efficacy of the vaccines (20, 29-33).

102  
103 The findings in (7) summarized the breakdown of primary infections, including cases requiring  
104 hospitalization, hospitalized cases requiring intensive critical care service (ICU hereafter), and  
105 death cases for different age groups. Another survey targeting reinfections showed the statistics of  
106 death, hospitalizations, and unclear/asymptomatic infections (8). The total cases in this study were  
107 comprised of four sections including primary infections, secondary infections, infections due to  
108 the inefficacy of vaccines after vaccination, and infections due to immunity waning of vaccines  
109 after vaccination. On the other hand, the total cases averted reflected the difference in the number  
110 of infections between a primary and a booster strategy, the gap for which could be attributable to  
111 multiple factors including the immunity profiles of vaccines, landscape of vaccination, traits of  
112 the pathogen, and rate of rollout. To capture the stratified effect of disease burdens in detail, the  
113 model divided the initial total cases averted into five stratified health metrics including  
114 symptomatic, asymptomatic, hospitalized, ICU, and death cases averted, and the statistics of these  
115 measures were calculated respectively based on the statistics data in (7) and (8). Additionally, the  
116 model assumed: (a) the population was homogenous and identical population size of each age  
117 group; (b) individuals with at least one dose vaccinated were infected with no symptoms (i.e.,  
118 asymptomatic) due to partial immunity protection of vaccines; (c) the relative infectiousness of  
119 other types of infections was identical to the primary infections; (d) the primary vaccination was  
120 initiated at week 44, nearly eleven months after the establishment of the transmission; (e) to  
121 reflect seasonal variation in transmission, the model based seasonal reproduction numbers in this  
122 work on those used in (5), which calibrated values to yield the basic reproduction number of 2.3;  
123 (f) no constraint of population size was present; (g) the primary vaccination consisted of two doses,  
124 and the booster vaccination consisted of one dose or above.

125  
126 For purpose of clarity and brevity, the main analysis illustrated the aversion/trade-off effect for a  
127 setting with a one-billion population size over an observation period of four years (i.e.,  
128 equivalently 208 weeks assuming one year consists of 52 weeks) by using a discrete measure of  
129 SI from 0.1 to 0.9 in 0.1 increments. I also reflected other varying sizes of populations (i.e.,  $8e7$  to  
130  $1.2e9$ ), diverse lengths of observation time (i.e., 160 to 260 weeks), varying SI measured in a  
131 continuous scale, and other key parameters in the online interactive dashboard (34). The  
132 sensitivity tests on other sizes of populations and intervals of observations were comparable and  
133 generalizable. The robustness tests using a series of key parameters implied that the outcomes  
134 were consistent for up to 5 years (Supplementary Material and online interactive dashboard).

## 135 136 137 **Results**

### 138 **Cyclical trajectory changed with vaccine profiles and vaccination strategies**


139 The model implied that, for a basic reproduction number  $R_0 = 2.3$ , the dynamic trajectory of the  
140 cyclical pandemic changed with the SI of booster doses over four years. The appraised scenarios  
141 could be classified into three categories: high- (Fig. 1, A to C), medium- (Fig. 1, D to F), and low-  
142 risk resurgence respectively (Fig. 1, G to I). The risk of cyclical resurgence of the epidemic  
143 decreased with the reduction of SI values (Fig. 1, A to F). The lower-risk scenario had fewer  
144 times of reoccurrence and the pandemic was contained at an earlier time versus the other two  
145 scenarios. On the other, the peak sizes of subsequent resurgence after week 156 (i.e., nearly 80

146 weeks after the initiation timing of booster doses) for the lower-risk scenario were smaller in  
147 magnitude versus the higher-risk counterpart as well (Fig. 1, G, H, and I versus D, E, and F versus  
148 A, B, and C).

149  
150 When the immunity strength of vaccines was productive (Fig. 1, I), both primary and booster  
151 vaccination contained the pandemic in three years. Distribution of booster doses reduced the peak  
152 sizes of the pandemic versus the primary strategy, which was curtailed more in terms of  
153 magnitude with the increase in the rollout rate of booster doses. A higher-rate rollout contained  
154 the pandemic at an earlier time versus a lower-rate rollout. Asymptotically, the difference in the  
155 containment timing of the pandemic between the higher-rate and the lower-rate scenario was 68  
156 weeks (i.e., week 88 versus week 156). When SI increased to 0.2 and the effectiveness of  
157 vaccines reduced (Fig. 1, H), the curtailing effect resulting from booster vaccination decreased.  
158 No differentiated aversion effect of peak sizes was observed by enhancing the rollout rate of  
159 doses versus the lower-rate scenarios. A similar trend was captured when SI was equal to 0.3 (Fig.  
160 1, G). In the medium- and high-risk scenarios, booster vaccination reduced the transmission in the  
161 short run (i.e., before week 104), however, cyclical resurgences of the pandemic were likely to  
162 occur in the long run (Fig. 1, A to F).

163  
164 Substantial weekly cases were averted in a short period in the cases where the rollout of booster  
165 doses was productive (Fig. 2, I), which facilitated the expeditious mitigation and depletion of the  
166 transmission. And the higher-rate scenario was expected to attain a greater aversion in magnitude  
167 versus the lower-rate counterpart. For instance, 514026 weekly cases were averted for the former  
168 (i.e., a rate equal to 4 per year) versus 333809 weekly cases averted for the latter (i.e., a rate equal  
169 to 0.5 per year) at week 80 (Fig. 2, I). When SI increased, the weekly difference of cases averted  
170 between the higher- and lower-rate strategy decreased. From a long-term perspective, the positive  
171 effect of aversion resulting from booster doses transformed into a negative effect with the  
172 increase of SI values (Figs. 2, A to H).

173  
174



175  
176

177 **Fig. 1. Simulated trajectory of cyclical resurgence.** The impact of immunity profiles of  
178 vaccines and social efforts on the cyclical occurrences of a COVID-19-like pandemic over four  
179 years assuming one year is comprised of 52 weeks. SI varies from 0.9 (A) to 0.1 (I) in 0.1 discrete  
180 increments. For each SI scenario, the primary strategy consists of two doses, and the higher and  
181 lower rollout rate of booster doses is equal to 4 and 0.5 per year, mimicking scenarios of  
182 productive and non-productive distribution respectively. Shaded light-color areas delineate the  
183 95% confidence intervals of the simulations. Orange color bars represent the spacing between the  
184 primary doses, and the dashed orange line describes the initiation timing of booster doses. For  
185 clarity, I illustrate the trajectory for an 8-week primary spacing and a 24-week booster spacing.  
186  
187  
188



217 hereafter CI) cases averted, and the latter  $3.282357e+08$  (CI: 194672962, 461798377) cases  
218 averted at the peak points respectively (Fig. 3, I1, and Supplementary data file S1). The aversion  
219 rate was roughly 81.9% for the higher- and 32.8% for the lower-rate rollout respectively divided  
220 by an assumed one-billion population size taking into account the risks of reinfections, the  
221 difference in vaccination strategies, the traits of disease transmission, and the traits of vaccines.  
222 For each stratified metric under the same level of SI, the cases averted remained at the  
223 commensurate level relative to the peak sizes at the end of appraisal time, implying a robust and  
224 consistent aversion effect when SI values were lower. In a salient-effect scenario, a higher-  
225 capacity rollout could capture an effect of more than double-fold versus the lower-capacity  
226 counterpart (Fig. 3, I1 to I6, and Supplementary data file S1). When SI transferred to the medium-  
227 salient scenario in which  $SI=0.2$  (Fig. 3, H1), the cases averted for the total cases dropped versus  
228 the high-salient scenario in which  $SI=0.1$  (Fig. 3, I1). Asymptotically, the peak date shifted to  
229 week 137 for the higher- and week 133 for the lower-rate scenario, the peak size of which was  
230  $285826987$  (CI: 167652930, 404001045) for the former and  $223255075$  (CI: 134128570,  
231  $312381581$ ) for the latter respectively (Fig. 3, H1, and Supplementary data file S1). This implied  
232 a nearly 28.6% and 22.3% aversion rate under the same size of the population previously. In the  
233 medium- and high-salient cases, the size averted for the total cases decreased over time after the  
234 peak-date point (Fig. 3, A1, B1, C1, D1, E1, F1, G1, and Supplementary data file S1). In a similar  
235 vein, at  $SI=0.3$ , the peak date observed was at the commensurable point of time for the higher-  
236 versus for the lower-rate scenario, and  $247459708$  (CI: 146289736, 348629681) versus  
237  $2.378337e+08$  (CI: 140641248, 335026083) in magnitude respectively (Fig. 3, G1, and  
238 Supplementary data file S1). It could be seen that with the increase of SI, the gap of cases averted  
239 between productive and non-productive rollout lessened or reversed at certain points (Fig. 3, A1,  
240 B1, C1, D1, E1, F1, and Supplementary data file S1), suggesting the limited effect of rollout  
241 capacity enhancing and the complexity of the transmission when vaccines were ineffective. The  
242 greater values of SI, the faster reduction in the cases averted over time after the peak points,  
243 indicating the earlier terminating of the positive effect (Fig. A1, B1, C1, D1, E1, F1, G1, H1, and  
244 Supplementary data file S1).

245


246 Consistently, the trending observed for total cases averted applied to the other five stratified  
247 disease burdens including symptomatic, asymptomatic, hospitalized, ICU, and death cases averted  
248 when  $SI=0.1$  (Fig. 3, A2 to I6). For instance, the estimated peak date for maximum symptomatic  
249 cases averted was week 146 for the higher- versus week 115 for the lower-rate scenario, and the  
250 peak size averted was  $3.373556e+08$  (CI: 175563367, 499147914) versus  $9.617363e+07$  (CI:  
251  $62891532$ ,  $129455724$ ) (Fig. 3, I2, and Supplementary data file S1), implying a 33.74% and  
252 9.62% aversion rate respectively. In a comparable analysis, asymptomatic cases averted observed  
253 the peak date of week 146 versus week 128, and the peak size averted of  $4.189621e+08$  (CI:  
254  $224273867$ ,  $613650426$ ) versus  $2.154589e+08$  (CI: 127649753, 303268108) respectively (Fig. 3,  
255 I3, and Supplementary data file S1), indicating a 41.9% and 21.55% aversion rate. As for  
256 hospitalization cases averted, the data yielded the peak date of week 146 versus week 128, and the  
257 peak size averted of  $4.795871e+07$  (CI: 25191367, 70726047) versus  $1.562443e+07$  (CI: 9089754,  
258  $22159110$ ) (Fig. 3, I4, and Supplementary data file S1), the aversion rates of which were 5.00%  
259 and 1.56% respectively. The peak date for ICU cases averted was estimated at week 146 versus  
260 week 128, and the peak size averted captured a magnitude difference of  $9591741$  (CI: 5038273,  
261  $14145209$ ) versus  $3.124887e+06$  (CI: 1817950, 4431822) (Fig. 3, I5, and Supplementary data file  
262 S1). Analogous calculation yielded aversion rates of 1% and 0.3%. Finally, death cases averted  
263 estimated the saturation points of week 146 versus 129, and the saturation size averted of  
264  $2.745773e+07$  (CI: 14578065, 40337389) versus  $1.249529e+07$  (CI: 7122512, 17868064) (Fig. 3,  
265 I6, and Supplementary data file S1), for which the aversion rates were 2.75% and 1.25%. To sum  
266 up, when SI was low, enhancing the rollout rate of booster doses increased the cases averted and

267 the effect of aversion was robust over time after the peak dates for symptomatic, asymptomatic,  
268 hospitalized, ICU, and death cases. The peak dates were reached approximately after 61 to 70  
269 weeks of the rollout for the higher-rate scenario and 39 to 52 weeks for the lower-rate scenario,  
270 suggesting the complexity of the disease transmission.

271  
272 In the scenarios where the SI value increased to 0.2, the cases averted for each of the stratified  
273 disease burdens reduced in magnitude (Fig. 3, H1 to H6). Representatively, symptomatic cases  
274 averted observed the homogeneous peak date of week 119, whereas the peak size of 77612795  
275 (CI: 49790759, 105434831) for the high- versus 59550066 (CI: 39163409, 79936723) for the  
276 low-capacity scenario (Fig. 3, H2, and Supplementary data file S1), which resulted in a 7.76%  
277 and 5.96% aversion rate respectively. Likewise, the simulation forecast the peak date of week 140  
278 versus week 136 for asymptomatic cases averted, and the peak size averted of 192469959 (CI:  
279 112526792, 272413128) versus 1.516442e+08 (CI: 90813414, 212474984) (Fig. 3, H3, and  
280 Supplementary data file S1), producing a 19.25% and 15.16% aversion rate. For the  
281 hospitalization scenario, the projected values were week 144 versus week 131, and 12883256 (CI:  
282 7331233, 18435280) versus 10212040 (CI: 6039796, 14384285) (Fig. 3, H4, and Supplementary  
283 data file S1), yielding the aversion rate of 1.29% and 1%. The ICU scenario observed week 132  
284 versus week 131, and peak size averted of 2654109 (CI: 1543704, 3764514) versus 2042408 (CI:  
285 1207959, 2876857) (Fig. 3 H5, and Supplementary data file S1), from which computing the  
286 aversion rate of 0.3% versus 0.2%. Finally, the peak date of week 142 versus week 139 for death  
287 cases averted, and the peak size averted of 10742189 (CI: 6086897, 15397481) versus 8460058  
288 (CI: 4877025, 12043092) (Fig. 3, H6, and Supplementary data file S1), representing the aversion  
289 rate of 1% and 0.8%. The peak dates were reached with a slightly earlier time for the higher-rate  
290 scenario versus SI=0.1.

291  
292  
293 When the SI value increased to 0.3 or greater, the cases averted decreased further for each  
294 stratified disease burden (Fig. 3, A1 to G6, and Supplementary data file S1). The gap of cases  
295 averted for each metric reduced or reversed between higher- and lower-capacity scenarios when  
296 SI inflated. Taking the scenario SI=0.3 as an illustration, the peak size averted for symptomatic  
297 cases curtailed to 61559292 (CI: 38861942, 84256642) versus 58618482 (CI: 37067324,  
298 80169641) (Fig. 3, G2, and Supplementary data file S1). The asymptomatic cases averted  
299 observed similar trending, the peak size averted downsized to 1.703002e+08 (CI: 100268604,  
300 240331865) versus 1.641417e+08 (CI: 96645891, 231591011) (Fig. 3, G3, and Supplementary  
301 data file S1). This lowered to 1.106625e+07 (CI: 6444994, 15687515) versus 1.059409e+07 (CI:  
302 6169283, 15018895) for hospitalized cases (Fig. 3, G4, and Supplementary data file S1). And the  
303 peak ICU cases averted shrank to 2213250 (CI: 1288998, 3137502) versus 2.118818e+06 (CI:  
304 1233856, 3003778) (Fig. 3, G5, and Supplementary data file S1). Finally, peak death cases  
305 averted dropped to 9249231 (CI: 5263545, 13234918) versus 8.902579e+06 (CI: 5064754,  
306 12740403) respectively (Fig. 3, G6, and Supplementary data file S1). The positive role played by  
307 enhancing the rollout rate of booster doses reduced with the increase of SI values. Greater values  
308 of SI also curtailed the magnitude of aversion and terminate the positive aversion effect earlier  
309 versus lower values.






**Fig. 3. Simulation stratified cases averted for six major disease burdens.** Simulation of the aversion effect for major metrics of health outcomes with SI ranging from 0.9 (A1 to A6) to 0.1 (I1 to I6) in 0.1 increments. All scenarios sketch the cumulative cases averted over four years. “Total averted” scenario denotes the total cases averted; “Symp. averted” depicts the symptomatic cases averted; “Asym. averted” represents the asymptomatic cases averted; “Hosp. averted” represents the hospitalization cases averted; “ICU averted” outlines the number averted of patients needing intensive care unit; “Death averted” delineates the death cases averted. For each SI scenario, higher (purple curves and shaded areas) and lower (green curves and shaded areas) rollout rates of booster doses are equal to 4 and 0.5 per year respectively. Shaded light colors sketch the 95% confidence intervals of the simulations. A more detailed continuous measure of SI, differentiated rollout rates of booster doses, diverse booster spacing, varying length of observation time, and other key parameters are delineated in the online interactive dashboard.

## Trade-offs when immunity profiles of vaccines transformed to suboptimal


I estimated the trade-offs for the stratified cases averted over four years when the immunity profiles of booster doses changed to suboptimal by varying SI and VI from 0 to 1.0 using 50 simulations for each measure using the previous population size *ceteris paribus* (Fig. 4, A to F). The main analysis illustrated the outcomes for the higher-rate rollout scenario, and the lower-rate scenario implied a similar effect of trending (Fig. S25, A to F). The parameters used in the simulation were outlined in the Supplementary Material (Table S2). Consistently, all the stratified health metrics including total, symptomatic, asymptomatic, hospitalized, ICU, and death cases averted observed positive trade-offs when the values of SI and VI were lower (i.e., the areas where values asymptotically lower than 0.2), and negative trade-offs when suboptimal (i.e., the areas where values asymptotically greater than 0.2). For instance, when VI=0.3 and SI=0.3 *ceteris paribus*, the estimate asymptotically yielded the negative trade-offs of  $-5e8$  cases for total cases averted (Fig. 4, A),  $-4e7$  cases for symptomatic cases averted (Fig. 4, B),  $-4e8$  cases for asymptomatic cases averted (Fig. 4, C),  $-2e7$  cases for hospitalized cases averted (Fig. 4, D),  $-5e6$  cases for ICU cases averted (Fig. 4, E), and  $-2e7$  cases for death cases averted using a population size of  $1e9$  respectively (Fig. 4, F). These values reflected the rates of social cost of 50%, 4%, 40%, 2%, 0.5%, and 2% respectively. The greater values of SI and VI, the larger effect of negative trade-offs.



**Fig. 4. Simulation trade-offs of disease burdens varying SI and VI from 0 to 1.** Simulation of the cumulative stratified cases averted over four years with SI and VI ranging from 0 to 1.0 using 50 simulations for each metric respectively. The population size is equal to  $1e9$ . Positive numbers on each curve illustrate the positive cases averted for each health outcome, and negative numbers depict the negative trade-off when VI and SI transform to sub-optimal ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

In this section, I performed analysis on the trade-offs for the same stratified health metrics with SI and VS varying from 0 to 1.0 using 50 simulations for each respectively (Fig. 5, A to F). Consistent with previous findings, all measures observed a positive aversion effect when VS and SI were lower. The effect transformed to negative trade-offs when VS and SI were suboptimal ceteris paribus. For instance, when VS=0.3 and SI=0.6, the range of trade-offs was approximately  $[-1e9, -5e8]$  for total cases averted (Fig. 5, A),  $[-6e7, -4e7]$  for symptomatic cases averted (Fig. 5, B),  $[-1e9, -5e8]$  for asymptomatic cases averted (Fig. 5, C),  $[-4e7, -2e7]$  for hospitalized cases averted (Fig. 5, D),  $[-1e7, -5e6]$  for ICU cases averted (Fig. 5, E), and  $[-4e7, -2e7]$  for death cases averted respectively (Fig. 5, F). These reflected the rate ranges of social cost of [50%, 100%], [4%, 6%], [50%, 100%], [2%, 4%], [0.5%, 1%], and [2%, 4%] respectively. The parameters used in the simulation and the outcomes were summarized in the Supplementary Material (Table S3,


371 Fig. S26, A to F). For constant values of SI in the higher range, increasing the values of VS raises  
 372 the magnitude of negative trade-offs, suggesting the salient role that VS played in the  
 373 transmission of diseases.  
 374  
 375



376  
 377 **Fig. 5. Simulation trade-offs of disease burdens with varying immunity profiles using VS**  
 378 **and SI.** Simulation of the cumulative stratified cases averted over four years with SI and VS  
 379 ranging from 0 to 1.0 using 50 simulations for each metric respectively. The population size  
 380 equal to one billion. Positive numbers on each curve illustrate the positive cases averted for each  
 381 health burden, and negative numbers depict the negative trade-off when VI and SI are sub-optimal  
 382 ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout  
 383 scenario.

384  
 385  
 386  
 387  
 388 **Positive cases averted when immunity profiles of vaccines are productive**  
 389

390 Next, I estimated how the values of SI and VI contributed to the positive effect of aversion by  
 391 concentrating on the interval  $[0, 0.1]$  where the immunity profiles of vaccines are productive, for  
 392 both measures (Fig. 6, A to F). The results implied that lower values of VI and SI reduced the  
 393 social cost and yielded a greater magnitude of effect versus higher-value counterparts for total,  
 394 symptomatic, asymptomatic, hospitalized, ICU, and death cases averted. For instance, when  
 395  $VI=0.05$  and  $SI=0.05$ , the cases averted were asymptotically  $8e7$  for total cases (Fig. 6, A),  $1e7$   
 396 for symptomatic cases (Fig. 6, B),  $6e7$  for asymptomatic cases (Fig. 6, C),  $3e6$  for hospitalized  
 397 cases (Fig. 6, D),  $6e5$  for ICU cases (Fig. 6, E), and  $3e6$  for death cases respectively (Fig. 6, F).  
 398 These produce the aversion rate of 8%, 1%, 6%, 0.3%, 0.06%, and 0.3% respectively.  
 399  
 400




401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410

**Fig. 6. Simulation stratified cases averted for disease burdens with SI and VI between 0 and 0.1.** Simulation of the stratified cases averted over four years for the six major health burdens with SI and VI varying from 0 to 0.1 using 50 simulations for each metric respectively. The population size is equal to  $1e9$ . Positive numbers on each curve illustrate the positive aversion effect, and negative numbers depict the negative trade-off for each health outcome when VI and SI are sub-optimal ceteris paribus. The rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427

The estimates of SI and VS varying from 0 to 0.1 were analyzed in a similar vein (Fig. 7, A to F). For a constant value of SI=0.04 and population size of 1e9, calibration of VS from 0.07 to 0.05 asymptotically engendered positive cases averted of 2e7 for total cases (Fig. 7, A), 2e6 for symptomatic cases (Fig. 7, B), 2e7 for asymptomatic cases (Fig. 7, C), 1e6 for hospitalized cases (Fig. 7, D), 2e5 for ICU cases (Fig. 7, E), and 1e6 for death cases (Fig. 7, F). In contrast, when VS=0.05 and SI=0.05, the cases averted were asymptotically [6e7,8e7] for total cases (Fig. 7, A), [8e6,1e7] for symptomatic cases (Fig. 7, B), [4e7, 6e7] for asymptomatic cases (Fig. 7, C), [2e6, 3e6] for hospitalized cases (Fig. 7, D), [4e5, 6e5] for ICU cases (Fig. 7, E), and [2e6, 3e6] for death cases respectively (Fig. 7, F). These outcomes reflected the rates of aversion effect of [6%, 8%], [0.8, 1%]. [4%, 7%], [0.2%, 0.3%],[0.04%, 0.06%], and [0.2%, 0.3%] respectively.



428  
429  
430  
431

**Fig. 7. Simulation stratified cases averted for major disease burdens with SI and VS.** Simulation of the stratified cases averted over four years for SI and VS varying from 0 to 0.1

432 using 50 simulations for each metric respectively. The population size is equal to 1e9. Positive  
433 numbers on each curve illustrate the positive aversion effect, and negative numbers depict the  
434 negative trade-off for each health outcome when VS and SI are sub-optimal ceteris paribus. The  
435 rollout rate of booster doses is 4 per year, representing the productive rollout scenario.

436  
437  
438

## 439 **Sensitivity tests of cases averted using major parameters**

### 440 **One-way sensitivity analysis**

441 I performed a series of sensitivity analyses on the stratified cases averted for all six disease  
442 burdens by employing key parameters of the transmission, traits of the pathogen, traits of  
443 vaccines, and vaccination strategies. For each of the parameters, changing a specific metric ceteris  
444 paribus to project the update of aversion trajectory.

445 *Rate of waning to susceptibility after vaccination.* Experiments conducted on recovered  
446 patients found heterogeneous levels of detectable SARS-CoV-2 neutralizing antibodies, implying  
447 a differentiated rate of immunity waning to susceptibility after vaccination (7-16, 25-29). I tested  
448 the sensitivity across high-, medium-, and low-risk scenarios for primary doses, and the major  
449 findings were robust (figs. S2 to S7).

450 *Rate of birth and death.* Considering the years of evaluation, the population might change  
451 during the period (20, 22-28). I estimated two scenarios corresponding to a slower rate and a  
452 faster rate of population change respectively. The outcomes did not change qualitatively (figs. S8  
453 to S9).

454 *Vaccination rate of primary doses.* Studies in (20-26,29-34) suggest that the vaccination rate of  
455 doses could impact the trajectory of disease transmission. I tested these scenarios and the  
456 outcomes remained qualitatively the same as in the main analysis (figs. S10 to S11).

457 *Vaccination rate of booster doses.* To test how the change in the vaccination rate of booster  
458 doses played roles in the trajectory of aversion effect (35-42), a greater rate and a slower rate  
459 were used respectively (fig. S12 to S13). Other rollout rates of booster doses can be found in the  
460 online interactive dashboard (34). The robustness test for this parameter also supported the  
461 consistency.

462 *Timing of vaccination of booster doses.* The timing of the vaccination potentially exerted an  
463 impact on the transmission and hence the aversion track (20, 43-48). I tested two scenarios by  
464 shifting the timing of booster doses to an earlier/delayed point respectively, and the results were  
465 qualitatively unchanged (figs. S14 to S15). As expected, delaying the rollout of booster doses  
466 yielded a curtailed aversion effect.

467 *Initial size of infections.* I tested the scenarios with greater and smaller sizes of initial infections  
468 respectively (20, 49-54), and the outcome remained at the commensurate level (figs. S16 to S17).  
469 The tests using a different initial ratio of secondary over primary infections also supported this  
470 robustness (34).

471 *Size of population.* The model did not place constraints on the population size. The main  
472 analysis presented the outcomes corresponding to a setting with one-billion population size  
473 (20,35-38). I also tested the scenario where the population size was equal to one-tenth of the one-  
474 billion size and the analysis implied a comparable outcome (fig. S18 to S22). For the effects on  
475 other sizes of populations, please refer to the online interactive dashboard (34).

476 *Rate of waning to secondary susceptibility after recovery.* Patients either obtained natural  
477 and/or vaccination immunity after recovery, which reduced over time and individuals could be

478 exposed to reinfections at a later time (20, 25-33). I tested the rate of waning to secondary  
479 susceptibility after recovery and the results qualitatively identified the robustness(34).

### 483 **Multiway sensitivity analysis**

484 Additionally, I selected seven parameters (susceptibility rate to infection after immunity of dose  
485 1&2 wanes, rate of waning to susceptibility after dose 1&2 vaccination, rate of infection after  
486 dose 1&2 vaccination, rate of waning to secondary susceptibility after recovery) for which the  
487 uncertainties were of concerns and tested two combinations of these major parameters (figs. S23  
488 to S24). The cases averted were quite robust in these analyses as well (figs. S23 to S24). For more  
489 detailed information regarding the length of observation time, continuous measure of SI, sizes of  
490 populations, initiation timing of booster vaccination, other key parameters, and how the  
491 responsiveness of the results to the parameters, please refer to the online interactive dashboard  
492 (34).

### 497 **Discussion**

498 The findings suggest that, assuming  $R_0 = 2.3$ , booster vaccines with low-risk immunity profiles  
499 could produce a salient effect for major disease burdens including total, symptomatic,  
500 asymptomatic, hospitalized, ICU, and death cases averted up to 5 years, the magnitude of which is  
501 followed by medium- and then high-risk counterparts respectively. Enhancing the rollout rate of  
502 booster doses yields a greater and more durable aversion effect over time after the peak points  
503 versus lower-rate rollout scenarios when SI was low, and the effect was reduced with the increase  
504 of SI values. In a setting with a one-billion of population size and SI=0.1, the peak aversion rate  
505 of total cases was approximately 81.9% for the higher-rate rollout (i.e., a rate equal to 4 per year)  
506 versus 32.8% for the lower-rate rollout (i.e., a rate equal to 0.5 per year), 33.74% versus 9.62%  
507 for peak symptomatic cases, 41.9% versus 21.55% for asymptomatic cases, 5.00% versus 1.56%  
508 for hospitalization cases, 1% versus 0.3% for ICU cases, 2.75% versus 1.25% for death cases  
509 respectively. These rates reduced to 28.6% versus 22.3%, 7.76% versus 5.96%, 19.25% versus  
510 15.16%, 1.29% versus 1%, 0.3% versus 0.2%, 1% and 0.8% respectively when SI=0.2 and lower  
511 when SI values were greater. Enhanced social effort facilitated the rapid mitigation and  
512 containment of the pandemic when SI was low, whereas the gap of the aversion effect was  
513 reduced when SI increased (20-23, 39-45). The greater values of SI, the faster reduction in the  
514 cases averted over time after the peak points and the earlier termination of the positive aversion  
515 effect. When immunity profiles of vaccines (e.g., SI, VI, and VS) transformed from productive to  
516 suboptimal, negative trade-offs were observed for all disease burdens. The findings were  
517 consistent with other vaccine modeling studies (20-28,54-55). The greater values of SI, VI, and  
518 VS, the larger the negative trade-offs generated. The results suggest that enhanced social effort  
519 through the rollout improvement of booster doses facilitated the control of disease transmission  
520 when the immunity profiles of doses were productive.

521  
522 Many countries used nearly three years or more to control and/or mitigate the spread of the  
523 COVID-19 pandemic, and the diminishing of the transmission reflected substantial collaborations  
524 and effort (35,39-45). Here, a compartment-refined model was utilized to determine the cases  
525 averted and trade-offs for stratified disease burdens up to 5 years. The outcomes were consistent



526 over time for total, symptomatic, asymptomatic, hospitalized, ICU, and death cases averted. I  
527 have assumed a plain framework for capturing the critical traits of SARS-CoV-2 booster vaccines  
528 or other infectious diseases that would partially share similar traits with SARS-CoV-2. Nearly 20  
529 years passed since the first outbreak of the SARS pandemic in 2003 (1-4,20-24), and it could be  
530 difficult to pinpoint the next risk. However, it is expected that when vaccines are available should  
531 a novel infectious disease emerge, more scientific knowledge about the mechanisms, including  
532 the viral load trajectory, the relationship with dynamic infectiousness, and the vaccination  
533 strategies would accrue over time, allowing refinement of the modeling and projection feasible  
534 (20-23,49-53). In practice, the magnitude of the effect can be updated by calibrating the  
535 parameters to new settings as more information unfolds.

536

537 This study has several limitations. First, the model assumed an equal and constant infectiousness  
538 profile for different types of infections including primary, secondary, and other infections.  
539 Scientific knowledge of the information for viruses and subsequent variant sub-lineages is  
540 incomplete and more observations are necessary, although some studies have made progress in  
541 this direction (26-31, 46-51). If the infectiousness profiles of different infections change over  
542 time, then the findings need to update when more accurate and dynamic data are available (20-  
543 25). Second, the model assumed a constant immunity-waning rate, infection/reinfection rate, and  
544 other rates, however, these conditions could modify in practice conditional on the transmission  
545 complexity of the pathogen and the traits of vaccines (20,32-39). As more detailed measures are  
546 available, the model can be recalibrated to reflect the updated information. Third, the model  
547 neither captured geographical/age/contact nor the primary-spacing differences, however, these  
548 factors potentially exerted a non-negligible impact on the stratified disease burdens (20-24, 31-  
549 35). As the population makeup, geographic traits, and social contacts could be very different  
550 across settings, and similarly the primary-dose spacing for vaccines. Potentially these were the  
551 key to determining region-, age-, contact-, and spacing-based estimates of cases averted and  
552 trade-offs. Fourth, I used the rates of various disease burdens published in (7) and (8), and the  
553 seasonal reproduction number published in (20) to project the potential impact, but these statistics  
554 might vary vastly over time and/or over locations. In these cases, models need to be refined and  
555 calibrated to reflect the temporal and geographic context. And the generalization of the results  
556 needed to be exercised with caution. Fifth, I assumed a two-dose primary strategy, which could  
557 be different for the differentiated practices in countries. Further, I used three critical traits of  
558 vaccines to estimate the stratified effect, whereas other important measures connected with the  
559 stratified disease burdens potentially present. For instance, occupation and vaccination hesitancy  
560 was potentially linked to an increased risk of asymptomatic and symptomatic infections in certain  
561 settings (12-18, 33-37). Furthermore, several studies (38-46) identified that, as a result of  
562 healthcare in-equilibrium, individuals from racial and ethnic minority groups were exposed to  
563 increased risk versus their counterparts in certain countries. These are critical considerations in  
564 further directions of studies to identify more detailed effects for the stratified disease burdens.

565

566 Finally, I have explored the simplest framework, which can only provide a general implication of  
567 the aversion potential for the stratified measures of health outcomes under different scenarios  
568 should a COVID-19-like pandemic occur. Including more complicated evolutionary components  
569 (20, 41-48) in the model is an important direction for future work. Heterogeneities of the  
570 pathogen, population makeup, vaccines, and vaccination strategies likely change chronically,  
571 which may have important impacts on the trajectory of peak dates, peak sizes, and trade-offs  
572 (20,35-38). The results can asymptotically provide an estimate of the traits of the pathogen, traits  
573 of the transmission, vaccines paired with social effort for stratified metrics of disease burdens,

574 which can be used as long-term evidence-based guidance to the retrospective threshold appraisal  
575 of vaccination strategies, social gains/costs and the stratified trade-off analysis in the long term.  
576  
577

## 578 579 **References**

- 580 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int> (2023).
- 581 2. World Health Organization. WHO COVID-19 vaccines. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines)  
582 [coronavirus-2019/covid-19-vaccines](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines) (2023).
- 583 3. World Health Organization. WHO COVID-19 vaccines. [https://www.who.int/publications/m/item/draft-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)  
584 [landscape-of-covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines) (2023).
- 585 4. World Health Organization. Interim statement on booster doses for COVID-19 vaccination.  
586 [https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination-](https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination--update-22-december-2021)  
587 [--update-22-december-2021](https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination--update-22-december-2021) (2022).
- 588 5. B.A. Filardi, V.S. Monteiro, P.V. Schwartzmann, V.P. Martins, L.E.R. Zucca, G.C. Baiocchi, A.A. Malik, J.  
589 Silva, A.M. Hahn, N.F. G. Chen, K. Pham, E. Perez-Then, M. Miric, V. Brache, L. Cochon, R.A. Larocca,  
590 R.D.R. Mendez, D. B. Silveira, A.R. Pinto, J. Croda, I. Yildirim, S.B. Omer, A.I. Ko, S.H. Vermund, N.D.  
591 Grubaugh, A. Iwasaki, C. Lucas, Yale SARS-COV-2 Genomic Surveillance Initiative. Age-dependent  
592 impairment in antibody responses elicited by a homologous CoronaVac booster dose. *Sci. Transl. Med.* 15,  
593 683(2023).
- 594 6. O.J. Wouters, K.C. Shadlen, M. Salcher-Konrad, A.J. Pollard, H.J. Larson, Y. Teerawattananon, M. Jit.  
595 Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and  
596 deployment. *Lancet* 397,1023–34(2021).
- 597 7. N.M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia, A. Boonyasiri,  
598 Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K. Gaythorpe, W. Green, A. Hamlet, W.  
599 Hinsley, L.C. Okell, S.V. Elsland, H. Thompson, R. Verity, E. Volz, H. Wang, Y. Wang, P. G.T. Walker, C.  
600 Walters, P. Winskill, C. Whittaker, C.A. Donnelly, S. Riley, A.C. Ghani. Impact of non-pharmaceutical  
601 interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. DOI: 10.25561/77482.
- 602 8. X.Y. Ren, J. Zhou, J. Guo, C.M. Hao, M.X. Zheng, R. Zhang, Q. Huang, X.M. Yao, R.L. Li, Y.H. Jin.  
603 Reinfection in patients with COVID-19: a systematic review. *Glob. Health Res. Policy*, 7:12(2022).
- 604 9. J.Y. Chung, M.N. Thone, Y.J. Kwon. COVID-19 vaccines: The status and perspectives in delivery points  
605 of view. *Adv. Drug. Deliv. Rev.* 170, 1–25 (2021).
- 606 10. S.A. Meo, I.A. Bukhari, J. Akram, A.S. Meo, D.C. Klonoff. COVID-19 vaccines: comparison of  
607 biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.  
608 *Eur. Rev. Med. Pharmacol. Sci.* 25, 1663-1669 (2021).
- 609 11. Mathieu, E. et al. A global database of COVID-19 vaccinations. *Nat. Hum. Behav.* 5,947-953 (2021).
- 610 12. Our World in Data. Statistics and Research Coronavirus (COVID-19) Vaccinations.  
611 <https://ourworldindata.org/covid-vaccinations> (Accessed on January 5, 2022).
- 612 13. E.A. Harrison, J.W. Wu. Vaccine confidence in the time of COVID-19. *Eur. J. Epidemiol.* 35, 325-330  
613 (2020).
- 614 14. N.S. Jecker, Z. Lederman. Three for me and none for you? An ethical argument for delaying COVID-19  
615 boosters. *J. Med. Ethics.* ,10.1136/medethics-2021-107824 (2021).
- 616 15. D.M. Skowronski, G.D. Serres. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl.*  
617 *J. Med.* 384, 1576-1577 (2021).
- 618 16. E. Vasileiou, C.R. Simpson, T. Shi, S. Kerr, U. Agrawal, A. Akbari, S. Bedston, J. Beggs, D. Bradley, A.  
619 Chuter, S. de Lusignan, A.B. Docherty, D. Ford, F.R. Hobbs, M. Joy, S.V. Katikireddi, J. Marple, C.  
620 McCowan, D. McGagh, J. McMenemy, E. Moore, J.L. Murray, J. Pan, L. Ritchie, S.A. Shah, S. Stock, F.  
621 Torabi, R.S. Tsang, R. Wood, M. Woolhouse, C. Robertson, A. Sheikh. Interim findings from first-dose  
622 mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national  
623 prospective cohort study. *Lancet* 397, 1646–57(2021).
- 624 17. Y.N. Lamb. BNT162b2 mRNA COVID-19 Vaccine: First Approval. *Drugs* 81(4), 495–501 (2021).
- 625 18. J. Sadoff, G. Gray, A. Vandebosch, V. Cárdenas, G. Shukarev, B. Grinsztejn, P.A. Goepfert, C. Truysers, H.  
626 Fennema, B. Spiessens, K. Offergeld, G. Scheper, K.L. Taylor, M.L. Robb, J. Treanor, D.H. Barouch, J.  
627 Stoddard, M.F. Ryser, M.A. Marovich, K.M. Neuzil, L. Corey, N. Cauwenberghs, T. Tanner, K. Hardt, J.  
628 Ruiz-Guiñazú, M. L. Gars, H. Schuitemaker, J.V. Hoof, F. Struyf, M. Douoguih, ENSEMBLE Study  
629 Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N. Engl. J. Med.*

- 630 384,2187-201 (2021).
- 631 19. D.V. Mehrotra, H.E. Janes, T.R. Fleming, P.W. Annunziato, K.M. Neuzil, L.N. Carpp, D. Benkeser, E.R.
- 632 Brown, M. Carone, I. Cho, D. Donnell, M.P. Fay, Y. Fong, S. Han, I. Hirsch, Y. Huang, Y. Huang, O.
- 633 Hyrien, M. Juraska, A. Luedtke, M. Nason, A. Vandebosch, H. Zhou, M.S. Cohen, L. Corey, J. Hartzel,
- 634 D. Follmann, P.B. Gilbert Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trial. *Ann.*
- 635 *Intern. Med.* 174(2):221-228 (2021).
- 636 20. C.M. Saad-Roy, S.E. Morris, C. J. E. Metcalf, M.J. Mina, R.E. Baker, J. Farrar, E.C. Holmes, O.G. Pybus,
- 637 A.L. Graham, S.A. Levin, B.T. Grenfell, C.E. Wagner. Epidemiological and evolutionary considerations of
- 638 SARS-CoV-2 vaccine dosing regimes. *Science* 372, 363-370 (2021).
- 639 21. B. Experton, H.A. Tetteh, N. Lurie, P. Walker, A. Elena, C.S. Hein, B. Schwendiman, J.L. Vincent, C.R.
- 640 Burrow. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science* 371,
- 641 916–921 (2021).
- 642 22. L. Corey, J.R. Mascola, A.S. Fauci, F.S. Collins. A strategic approach to COVID-19 vaccine R&D.
- 643 *Science* 368, 948-950 (2020).
- 644 23. S. Mallapaty. Researchers fear growing COVID vaccine hesitancy in developing nations. *Nature*,
- 645 10.1038/d41586-021-03830-7(2021).
- 646 24. P.R. Krause, T.R. Fleming, R. Peto, I.M. Longini, J.P. Figueroa, J.A.C. Sterne, A. Cravioto, H. Rees, J.P.T.
- 647 Higgins, I. Boutron, H. Pan, M.F. Gruber, N. Arora, F. Kazi, R. Gaspar, S. Swaminathan, M.J. Ryan, A.M.
- 648 Henao-Restrepo. Considerations in boosting COVID-19 vaccine immune responses. *Lancet* 398, 1377–80
- 649 (2021).
- 650 25. M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, B. Angus, V.L. Baillie,
- 651 S.L. Barnabas, Q.E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A.M. Collins, R. Colin-Jones, C.L. Cutland,
- 652 T.C. Darton, K. Dheda, C.J.A. Duncan, K.R.W. Emary, K.J. Ewer, L. Fairlie, S.N. Faust, S. Feng, D.M.
- 653 Ferreira, A. Finn, A.L. Goodman, C.M. Green, C.A. Green, P.T. Heath, C. Hill, H. Hill, I. Hirsch, S.H.C.
- 654 Hodgson, A. Izu, S. Jackson, D. Jenkin, C.C.D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A.M.
- 655 Lawrie, A. Lelliott, V. Libri, P.J. Lillie, R. Mallory, A.V.A. Mendes, E.P. Milan, A.M. Minassian, A.
- 656 McGregor, H. Morrison, Y.F. Mujadidi, A. Nana, P.J. O'Reilly, S.D. Padayachee, A. Pittella, E. Plested,
- 657 K.M. Pollock, M.N. Ramasamy, S. Rhead, A.V. Schwarzbald, N. Singh, A. Smith, R. Song, M.D. Snape,
- 658 E. Sprinz, R.K. Sutherland, R. Tarrant, E.C. Thomson, M.E. Török, M. Toshner, D.P.J. Turner, J.
- 659 Vekemans, T.L. Villafana, M.E.E. Watson, C.J. Williams, A.D. Douglas, A.V.S. Hill, T. Lambe, S.C.
- 660 Gilbert, A.J. Pollard, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19
- 661 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in
- 662 Brazil, South Africa, and the UK. *Lancet* 397,99-111 (2021).
- 663 26. S.A. Halperin. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of
- 664 recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an
- 665 international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. *Lancet* 399, 237-
- 666 248 (2021).
- 667 27. G. Troiano. Vaccine hesitancy in the era of COVID-19. *Public Health* 194, 245-251 (2021).
- 668 28. R. Verbeke, I. Lentacker, S.C. De Smedt, H. Dewitte. The dawn of mRNA vaccines: The COVID-19 case.
- 669 *J. Control Release.* 333, 511–520 (2021).
- 670 29. S. Yang, Y. Li, L. Dai, J. Wang, P. He, C. Li, X. Fang, C. Wang, X. Zhao, E. Huang, C. Wu, Z. Zhong, F.
- 671 Wang, X. Duan, S. Tian, L. Wu, Y. Liu, Y. Luo, Z. Chen, F. Li, J. Li, X. Yu, H. Ren, L. Liu, S. Meng, J. Yan,
- 672 Z. Hu, L. Gao, G.F. Gao. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based
- 673 protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-
- 674 controlled, phase 1 and 2 trials. *Lancet Infect. Dis.* 21, 1107–19 (2021).
- 675 30. N.A. Charania, S.M. Moghadas. Modelling the effects of booster dose vaccination schedules and
- 676 recommendations for public health immunization programs: the case of *Haemophilus influenzae* serotype
- 677 b. *BMC Public Health* 17, 705 (2017).
- 678 31. Experton, B. et al. A Predictive Model for Severe COVID-19 in the Medicare Population: A Tool for
- 679 Prioritizing Primary and Booster COVID-19 Vaccination. *Biology* 10, 1185 (2021).
- 680 32. Katikireddi, S.V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital
- 681 admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
- 682 *Lancet*, 10.1016/S0140-6736(21)02754-9 (2021).
- 683 33. N. Barda, N. Dagan, C. Cohen, M.A. Hernán, M. Lipsitch, I.S. Kohane, B.Y. Reis, R.D. Balicer.
- 684 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes
- 685 in Israel: an observational study. *Lancet* 2021, 398, 10316, 2093-2100 (2021).
- 686 34. Analysis of cases averted for stratified disease burdens during a COVID-19-like pandemic interactive
- 687 dashboard. [https://ichironakamoto.shinyapps.io/analysis\\_aversion\\_COVID-19-like\\_pandemic](https://ichironakamoto.shinyapps.io/analysis_aversion_COVID-19-like_pandemic).

- 688 35. A. Koirala, Y.J. Joo, A. Khatami, C. Chiu, P.N. Britton. Vaccines for COVID-19: The current state of play.  
689 Paediatr. Respir. Rev. 35, 43-49 (2020).
- 690 36. X. Wang, Z. Du, K.E. Johnson, R.F. Pasco, S.J. Fox, M. Lachmann, J.S. McLellan, L.A. Meyers. Effects  
691 of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. *Emerg. Infect.*  
692 *Dis.* 27(7), 1976-1979 (2021).
- 693 37. O. Milman, I. Yelin, N. Aharony, R. Katz, E. Herzal, A. Ben-Tov, J. Kuint, S. Gazit, G. Chodick, T. Patalon,  
694 R. Kishony. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.  
695 *Nat. Med.* 27, 1367–1369 (2021).
- 696 38. R.M. Kaplan, A. Milstein. Influence of a COVID-19 vaccine’s effectiveness and safety profile on  
697 vaccination acceptance. *PNAS* 118,10, e2021726118 (2021).
- 698 39. B.F. Haynes, L. Corey, P. Fernandes, P.B. Gilbert, P.J. Hotez, S. Rao, M.R. Santos, H. Schuitemaker, M.  
699 Watson, A. Arvin. Prospects for a safe COVID-19 vaccine. *Sci. Transl. Med.* 12, eabe0948 (2020).
- 700 40. A.A. Dror, N. Eisenbach, S. Taiber, N.G. Morozov, M. Mizrahi, A. Zigron, S. Srouji, E. Sela. Vaccine  
701 hesitancy: the next challenge in the fight against COVID-19. *Eur. J. Epidemiol.* 35,775–779 (2020).
- 702 41. S. Kashte, A. Gulbake, S.F. El-Amin, A. Gupta. COVID-19 vaccines: rapid development, implications,  
703 challenges, and future prospects. *Hum. Cell* 34, 711–733 (2021).
- 704 42. J. Wu, Q. Li, C.S. Tarimo, M. Wang, J. Gu, W. Wei, M. Ma, L. Zhao, Z. Mu, Y. Miao. COVID-19 Vaccine  
705 Hesitancy Among Chinese Population: A Large-Scale National Study. *Front. Immunol.* 12, 781161(2021).
- 706 43. S. Cele, L. Jackson, D.S. Khoury, K. Khan, T. Moyo-Gwete, H. Tegally, J.E. San, D. Cromer, C.  
707 Scheepers, D.G. Amoako, F. Karim, M. Bernstein, G. Lustig, D. Archary, M. Smith, Y. Ganga, Z. Jule, K.  
708 Reedoy, S.H. Hwa, J. Giandhari, J.M. Blackburn, B.I. Gosnell, K.S.S. Abdool, W. Hanekom, NGS-SA,  
709 COMMIT-KZN Team, A. Gottberg, J.N. Bhiman, R.J. Lessells, M.S. Moosa, M.P. Davenport, T. Oliveira,  
710 P.L. Moore, A. Sigal. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.  
711 *Nature* 602,654-656 (2021).
- 712 44. A. M. Ali1, K. M. Ali, M. H. Fatah, H. M. Tawfeeq, H. M. Rostam, SARS-CoV-2 reinfection in patients  
713 negative for immunoglobulin G following recovery from COVID-19. *New Microbes New Infect.* 43,  
714 100926 (2021).
- 715 45. D. Planas, N. Saunders, P. Maes, F. Guivel-Benhassine, C. Planchais, J. Buchrieser, W.H. Bolland, F.  
716 Porrot, I. Staropoli, F. Lemoine, H. Péré, D. Veyer, J. Puech, J. Rodary, G. Baele, S. Dellicour, J.  
717 Raymenants, S. Gorissen, C. Geenen, B. Vanmechelen, T. Wawina-Bokalanga, J. Martí-Carreras, L.  
718 Cuyppers, A. Sève, L. Hocqueloux, T. Prazuck, F.A. Rey, E. Simon-Loriere, T. Bruel, H. Mouquet, E. André,  
719 O. Schwartz. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* 602, 671-  
720 675 (2021).
- 721 46. H. Greter, S. Ivol, V.O. Mathieu, S. Erismann, H. Prytherch, P. Steinmann. Heterologous vaccine regimen:  
722 Stakeholder acceptance and implementation considerations. *Vaccine* 39, 580–587 (2021).
- 723 47. A. Shet, K. Carr, M.C. Danovaro-Holliday, S.V. Sodha, C. Prosperi, J. Wunderlich, C. Wonodi, H.W.  
724 Reynolds, I. Mirza, M. Gacic-Dobo, K.L. O'Brien, A. Lindstrand. Impact of the SARS-CoV-2 pandemic on  
725 routine immunisation services: evidence of disruption and recovery from 170 countries and territories.  
726 *Lancet Glob. Health.* 2022 10, 2, e186-e194.
- 727 48. C.J. Worby, H.H Chang. Face mask use in the general population and optimal resource allocation during  
728 the COVID-19 pandemic. *Nat. Commun.* 11, 4049 (2020).
- 729 49. K. Li, B. Huang, M. Wu, A. Zhong, L. Li, Y. Cai, Z. Wang, L. Wu, M. Zhu, J. Li, Z. Wang, W. Wu, W. Li,  
730 B. Bosco, Z. Gan, Q. Qiao, J. Wu, Q. Wang, S. Wang, X. Xia. Dynamic changes in anti-SARS-CoV-2  
731 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nat. Commun.* 11, 6044 (2020).
- 732 50. J.H. Kim, F. Marks, J.D. Clemens. Looking beyond COVID-19 vaccine phase 3 trials. *Nat. Med.* 27, 205–  
733 211 (2021).
- 734 51. R. Arbel, A. Hammerman, R. Sergienko, M. Friger, A. Peretz, D. Netzer, S. Yaron. BNT162b2 Vaccine  
735 Booster and Mortality Due to Covid-19. *N. Engl. J. Med.* 385, 2413-20(2021).
- 736 52. O.P. Misra, D.K. Mishra. Modelling the effect of booster vaccination on the transmission dynamics of  
737 diseases that spread by droplet infection. *Nonlinear Anal. Hybrid Syst.* 3, 657–665 (2009).
- 738 53. A.P.S. Munro, L. Janani, V. Cornelius, P.K. Aley, G. Babbage, D. Baxter, M. Bula, K. Cathie, K. Chatterjee,  
739 K. Dodd, Y. Enever, K. Gokani, A.L. Goodman, C.A. Green, L. Harndahl, J. Haughney, A. Hicks, A.A.  
740 Klaauw, J. Kwok, T. Lambe, V. Libri, M.J. Llewelyn, A.C. McGregor, A.M. Minassian, P. Moore, M.  
741 Mughal, Y.F. Mujadidi, J. Murira, O. Osanlou, R. Osanlou, D.R. Owens, M. Pacurar, A. Palfreeman, D.  
742 Pan, T. Rampling, K. Regan, S. Saich, J. Salkeld, D. Saralaya, S. Sharma, R. Sheridan, A. Sturdy, E.C.  
743 Thomson, S. Todd, C. Twelves, R.C. Read, S. Charlton, B. Hallis, M. Ramsay, N. Andrews, J.S. Nguyen-  
744 Van-Tam, M.D. Snape, X. Liu, S.N. Faust, COV-BOOST study group. Safety and immunogenicity of  
745 seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or

- 746 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet*  
747 398, 2258–76 (2021).
- 748 54. P.R. Krause, T.R. Fleming, R. Peto, I.M. Longini, J.P. Figueroa, J.A.C. Sterne, A. Cravioto, H. Rees, J.P.T.  
749 Higgins, I. Boutron, H. Pan, M.F. Gruber, N. Arora, F. Kazi, R. Gaspar, S. Swaminathan, M.J. Ryan, A.M.  
750 Henao-Restrepo. Considerations in boosting COVID-19 vaccine immune responses. *Lancet* 398, 10308,  
751 1377-1380 (2021).
- 752 55. E.J. Haas, J.M. McLaughlin, F. Khan, F.J. Angulo, E. Anis, M. Lipsitch, S.R. Singer, G. Mircus, N. Brooks,  
753 M. Smaja, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis. Infections,  
754 hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech  
755 BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. *Lancet Infect Dis* 22,  
756 357–66 (2022).

757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796

797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846

## **Acknowledgments**

I.N. acknowledges W. Chen for helpful discussions regarding the calibration analysis of parameters.

## **Funding:**

The study was partially supported by the following funding.

Undergraduate Teaching Reform Foundation of Fujian University and Technology grant 2022JG041

Graduate Teaching Reform and Textbook Publication Foundation of Fujian University and Technology grant YJC22-1

China Ministry of Education Industry and Education Cooperation Project grant 202002041005

National Social Science Foundation of China grant 22BGL007

Natural Science Funding of Fujian Province grant 2020J01892

Fujian Zhi-lian-yun Supply Chain Technology and Economy Integration Service Platform, Fujian-Kenya Silk Road Cloud Joint R&D Center grant 2021D021

Fujian Provincial Department of Science and Technology, the Fujian Social Sciences Federation Planning Project grant FJ2021Z006

General program of Fujian Natural Science Foundation grant 2022J01941

Fujian Provincial Department of Education Project grant JAT220230

Research Project of Major Education and Teaching Reform in Fujian Universities grant FBJG20190174

Initial Scientific Research Fund in Fujian University of Technology grant GY-Z220292

Fujian Provincial Department of Education Project grant JAT220230

## **Author contributions:**

I.N. conceived the study, developed the model, wrote the coding and performed analysis, and produced and revised the manuscript. All authors contributed to the final draft.

## **Competing interests:**

The author declares no competing interests.

## **Data and materials availability:**

All data needed to estimate the conclusions in the study are present in the paper, the Supplementary Materials, and/or the Supplementary Data. The code used in the analysis is available at [https://github.com/wcg305/prevention\\_cyclical\\_resurgence\\_COVID-19](https://github.com/wcg305/prevention_cyclical_resurgence_COVID-19). The interactive dashboard addressing the sensitivity tests and key parameters discussed in the manuscripts is accessible from the address [https://ichironakamoto.shinyapps.io/analysis\\_aversion\\_COVID-19-like\\_pandemic](https://ichironakamoto.shinyapps.io/analysis_aversion_COVID-19-like_pandemic). Additional data related to this paper may be requested from the corresponding author.

## **Supplementary Materials**

Please refer to the supplementary material for detailed information regarding the mathematical model, the parameters used in the simulations, and the results of the sensitivity tests.